{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.774","value":"1.36"},{"groupId":"OG001","spread":"0.955","value":"1.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Time to first response"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.774","value":"1.36"},{"groupId":"OG001","spread":"2.800","value":"2.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Time to best response"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.000","value":"0.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Time to VGPR or better response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered with 8 mg/kg daratumumab weekly once for 8 weeks, then every 2 week (q2w) for 16 weeks, then every 4 weeks (q4w) for up to 72 weeks or until the subject experienced disease progression or unmanageable toxicity, whichever came first (possible duration of treatment: 96 weeks). Along with methylprednisolone 100 mg IV before treatment and 20-25 mg methylprednisolone orally for 2 days after all full infusions.","id":"OG000","title":"Daratumumab 8 mg/kg"},{"description":"Participants were administered with 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then every 2 week (q2w) for 14 weeks, then every 4 weeks (q4w) for up to 72 weeks or until the subject experienced disease progression or unmanageable toxicity, whichever came first (possible duration of treatment: 96 weeks). Along with methylprednisolone 100 mg IV before treatment and 20-25 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.","id":"OG001","title":"Daratumumab 16 mg/kg"}],"paramType":"MEAN","populationDescription":"All-Treated Analysis Set included all enrolled participants who received at least 1 dose of study drug. Here 'n' (Number of Participants Analyzed) signifies number of participants analyzed at specific time point.","reportingStatus":"POSTED","timeFrame":"Up to Week 27","title":"Part 2: Time to Response","type":"SECONDARY","unitOfMeasure":"months"}